Which side effects will a nurse monitor for in a patient who has been prescribed topical clobetasol for psoriasis?

1. Dogra S, Yadav S. Psoriasis in India: Prevalence and pattern. Indian J Dermatol Venereol Leprol. 2010;76:595–601. [PubMed] [Google Scholar]

2. van de Kerkhof PC, Barker J, Griffiths CE, Kragballe K, Mason J, Menter A, et al. Psoriasis: Consensus on topical therapies. J Eur Acad Dermatol Venereol. 2008;22:859–70. [PubMed] [Google Scholar]

3. Bourke JF, Berth-Jones J, Hutchinson PE. Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris. Clin Exp Dermatol. 1993;18:504–6. [PubMed] [Google Scholar]

4. Patel T, Bhutani T, Busse KL, Koo J. Evaluating the efficacy and safety of calcipotriene/betamethasone ointment occluded with a hydrogel patch: A 6-week bilaterally controlled, investigator-blinded trial. Cutis. 2011;88:149–54. [PubMed] [Google Scholar]

5. Volden G, Kragballe K, van de Kerkhoffe PC, Aberg K, White RJ. Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing v/s twice daily treatment with clobetasol propionate alone. J Dermatol Treat. 2001;12:141–4. [PubMed] [Google Scholar]

6. Kaufmann R, Bibby AJ, Bissonnette R, Cambazard F, Chu AC, Decroix J, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology. 2002;205:389–93. [PubMed] [Google Scholar]

7. Vakirlis E, Kastanis A, Ioannides D. Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris. Ther Clin Risk Manag. 2008;4:141–8. [PMC free article] [PubMed] [Google Scholar]

8. Del Rosso J. Pharmacotherapy updates: Current therapies and research for common dermatologic conditions. The many roles of salicyclic acid. Skin Aging. 2005;13:38–42. [Google Scholar]

9. Green PG, Forbes DR, Kennedy CTC. The stability of dithranol in various bases. Br J Dermatol. 1985;113(s29):26. [Google Scholar]

10. van de Kerkhof PC, de Hoop D, de Korte J, Cobelens SA, Kuipers MV. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology. 2000;200:292–8. [PubMed] [Google Scholar]

11. Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. 2008;26:380–6. [PubMed] [Google Scholar]

12. Gelmetti C. Therapeutic moisturizers as adjuvant therapy for psoriasis patients. Am J Clin Dermatol. 2009;10(Suppl 1):7–12. [PubMed] [Google Scholar]

13. Syed TA, Ahmad SA, Holt AH, Ahmad SA, Ahmad SH, Afzal M. Management of psoriasis with Aloe vera extract in a hydrophilic cream: A placebo-controlled, double-blind study. Trop Med Int Health. 1996;1:505–9. [PubMed] [Google Scholar]

14. Paulsen E, Korsholm L, Brandrup F. A double-blind, placebo-controlled study of a commercial Aloe vera gel in the treatment of slight to moderate psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2005;19:326–31. [PubMed] [Google Scholar]

15. Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc. 2001;76:943–9. [PubMed] [Google Scholar]

16. Nola I, Kostovic K, Kotrulja L, Lugovic L. The use of emollients as sophisticated therapy in dermatology. Acta Dermatovenerol Croat. 2003;11:80–7. [PubMed] [Google Scholar]

17. McGill A, Frank A, Emmett N, Turnbull DM, Birch-Machin MA, Reynolds NJ. The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J. 2005;19:1012–4. [PubMed] [Google Scholar]

18. Mahrle G. Dithranol. Clin Dermatol. 1997;15:723–37. [PubMed] [Google Scholar]

19. Fleischmann HE. Short-contact anthralin therapy for psoriasis. West J Med. 1987;147:461. [PMC free article] [PubMed] [Google Scholar]

20. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: A systematic review. Br J Dermatol. 2002;146:351–64. [PubMed] [Google Scholar]

21. Jones SK, Campbell WC, Mackie RM. Out-patient treatment of psoriasis: Short contact and overnight dithranol therapy compared. Br J Dermatol. 1985;113:331–7. [PubMed] [Google Scholar]

22. Berth-Jones J, Chu AC, Dodd WA, Ganpule M, Griffiths WA, Haydey RP, et al. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol. 1992;127:266–71. [PubMed] [Google Scholar]

23. Hutchinson PE, Marks R, White J. The efficacy, safety and tolerance of calcitriol 3 microg/g ointment in the treatment of plaque psoriasis: A comparison with short-contact dithranol. Dermatology. 2000;201:139–45. [PubMed] [Google Scholar]

24. de Korte J, van der Valk PG, Sprangers MA, Damstra RJ, Kunkeler AC, Lijnen RL, et al. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: Quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting. Br J Dermatol. 2008;158:375–81. [PubMed] [Google Scholar]

25. Loffler H, Effendy I, Happle R. Skin susceptibility to dithranol: Contact allergy or irritation? Eur J Dermatol. 1999;9:32–4. [PubMed] [Google Scholar]

26. Ramsay B, Lawrence CM, Bruce JM, Shuster S. The effect of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol. 1990;23:73–6. [PubMed] [Google Scholar]

27. Wang JC, Krazmien RJ, Dahlheim CE, Patel B. Anthralin stain removal. J Am Acad Dermatol. 1986;15(5 Pt 1):951–5. [PubMed] [Google Scholar]

28. Kneczke M, Rahm C, Landersjö L. The influence of salicylic acid on the in vitro release of anthralin from an oil in water cream. Acta Pharm Nord. 1990;2:313–8. [PubMed] [Google Scholar]

29. Volden G, Björnberg A, Tegner E, Pedersen NB, Arlés UB, Agren S, et al. Short-contact treatment at home with micanol. Acta Derm Venereol. 1992;172:20–2. [PubMed] [Google Scholar]

30. Weller PJ, Newman CM, Middleton KR, Wicker SM. Stability of a novel dithranol ointment formulation, containing ascorbyl palmitate as an anti-oxidant. J Clin Pharm Ther. 1990;15:419–23. [PubMed] [Google Scholar]

31. Wulff-Woesten A, Ohlendorf D, Henz BM, Haas N. Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp. Skin Pharmacol Physiol. 2004;17:91–7. [PubMed] [Google Scholar]

32. Saraswat A, Agarwal R, Katare OP, Kaur I, Kumar B. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. J Dermatolog Treat. 2007;18:40–5. [PubMed] [Google Scholar]

33. Goeckerman W. Treatment of psoriasis. Northwest Med. 1925;24:229–31. [Google Scholar]

34. Arbiser JL, Govindarajan B, Battle TE, Lynch R, Frank DA, Ushio-Fukai M, et al. Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar. J Invest Dermatol. 2006;126:1396–402. [PubMed] [Google Scholar]

35. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol. 1999;41:51–9. [PubMed] [Google Scholar]

36. Slutsky JB, Clark RA, Remedios AA, Klein PA. An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis. J Drugs Dermatol. 2010;9:1258–64. [PubMed] [Google Scholar]

37. Sharma V, Kaur I, Kumar B. Calcipotriol versus coal tar: A prospective randomized study in stable plaque psoriasis. Int J Dermatol. 2003;42:834–8. [PubMed] [Google Scholar]

38. Khandpur S, Sahni K. An open label prospective randomized trial to compare the efficacy of coal tar-salicylic acid ointment versus calcipotriol/betamethasone dipropionate ointment in the treatment of limited chronic plaque psoriasis. Indian J Dermatol. 2014;59:579–83. [PMC free article] [PubMed] [Google Scholar]

39. Tham SN, Lun KC, Cheong WK. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol. 1994;131:673–7. [PubMed] [Google Scholar]

40. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol. 2001;45:487–98. [PubMed] [Google Scholar]

41. Lin AN, Moses K. Tar revisited. Int J Dermatol. 1985;24:216–8. [PubMed] [Google Scholar]

42. Maughan WZ, Muller SA, Perry HO, Pittelkow MR, O'Brien PC. Incidence of skin cancers in patients with atopic dermatitis treated with coal tar. A 25-year follow-up study. J Am Acad Dermatol. 1980;3:612–5. [PubMed] [Google Scholar]

43. Stern RS, Zierler S, Parrish JA. Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet. 1980;1:732–5. [PubMed] [Google Scholar]

44. Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol. 2008;59:295–315. [PubMed] [Google Scholar]

45. Frankel AJ, Zeichner JA, Del Rosso JQ. Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: Case report and clinical implications. J Clin Aesthet Dermatol. 2010;3:42–5. [PMC free article] [PubMed] [Google Scholar]

46. Alora-Palli MB, Perkins AC, Van Cott A, Kimball AB. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: A controlled comparison with calcipotriene (calcipotriol) cream. J Clin Dermatol. 2010;11:275–83. [PubMed] [Google Scholar]

47. Katare OP, Raza K, Singh B, Dogra S. Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors. Indian J Dermatol Venereol Leprol. 2010;76:612–21. [PubMed] [Google Scholar]

48. Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol. 1999;38:16–24. [PubMed] [Google Scholar]

49. Tiplica GS, Salavastru CM. Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23:905–12. [PubMed] [Google Scholar]

50. Carroll CL, Clarke J, Camacho F, Balkrishnan R, Feldman SR. Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch Dermatol. 2005;141:43–6. [PubMed] [Google Scholar]

51. Runne U. Anthralin-salicylic acid therapy of psoriasis. Cignolin-salicylic acid-vaseline treatment and Lasan paste in a right-left comparison. Hautarzt. 1974;25:199–200. [PubMed] [Google Scholar]

52. Zesch A. Short and long-term risks of topical drugs. Br J Dermatol. 1986;115(Suppl 31):63–70. [PubMed] [Google Scholar]

53. Chapman BJ, Proudfoot AT. Adult salicylate poisoning: Deaths and outcome in patients with high plasma salicylate concentrations. Q J Med. 1989;72:699–707. [PubMed] [Google Scholar]

54. Péc J, Strmenová M, Palencárová E, Pullmann R, Funiaková S, Visnovský P, et al. Salicylate intoxication after use of topical salicylic acid ointment by a patient with psoriasis. Cutis. 1992;50:307–9. [PubMed] [Google Scholar]

55. Germann R, Schindera I, Kuch M, Seitz U, Altmeyer S, Schindera F. Life threatening salicylate poisoning caused by percutaneous absorption in severe ichthyosis vulgaris. Hautarzt. 1996;47:624–7. [PubMed] [Google Scholar]

56. Taylor JR, Halprin KM. Percutaneous absorption of salicylic acid. Arch Dermatol. 1975;111:740–3. [PubMed] [Google Scholar]

57. van de Kerkhof PC, Vissers WH. The topical treatment of psoriasis. Skin Pharmacol Appl Skin Physiol. 2003;16:69–83. [PubMed] [Google Scholar]

58. Marsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: Mechanisms of action. Eur J Dermatol. 2002;12:618–22. [PubMed] [Google Scholar]

59. Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol. 1998;134:1101–2. [PubMed] [Google Scholar]

60. Gupta AK, Chow M. Pimecrolimus: A review. J Eur Acad Dermatol Venereol. 2003;17:493–503. [PubMed] [Google Scholar]

61. Wang C, Lin A. Efficacy of topical calcineurin inhibitors in psoriasis. J Cutan Med Surg. 2014;18:8–14. [PubMed] [Google Scholar]

62. Kreuter A, Sommer A, Hyun J, Bräutigam M, Brockmeyer NH, Altmeyer P, et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: A double-blind, randomized controlled study. Arch Dermatol. 2006;142:1138–43. [PubMed] [Google Scholar]

63. Ortonne JP, van de Kerkhof PC, Prinz JC, Bieber T, Lahfa M, Rubins A, et al. 0.3% tacrolimus gel and 0.5% tacrolimus cream show efficacy in mild to moderate plaque psoriasis: Results of a randomized, open-label, observer-blinded study. Acta Derm Venereol. 2006;86:29–33. [PubMed] [Google Scholar]

64. Lebwohl M, Gower T. A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. MedGenMed. 2006;8:8. [PMC free article] [PubMed] [Google Scholar]

65. Tauscher AE, Fleischer AB, Jr, Phelps KC, Feldman SR. Psoriasis and pregnancy. J Cutan Med Surg. 2002;6:561–70. [PubMed] [Google Scholar]

66. Brune A, Miller DW, Lin P, Cotrim-Russi D, Paller AS. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol. 2007;24:76–80. [PubMed] [Google Scholar]

67. Ormerod AD, Shah SA, Copeland P, Omar G, Winfield A. Treatment of psoriasis with topical sirolimus: Preclinical development and a randomized, double-blind trial. Br J Dermatol. 2005;152:758–64. [PubMed] [Google Scholar]

68. Duvic M, Asano AT, Hager C, Mays S. The pathogenesis of psoriasis and the mechanism of action of tazarotene. J Am Acad Dermatol. 1998;39(4 Pt 2):S129–33. [PubMed] [Google Scholar]

69. Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48:760–7. [PubMed] [Google Scholar]

70. Lebwohl M, Ast E, Callen JP, Cullen SI, Hong SR, Kulp-Shorten CL, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;38(5 Pt 1):705–11. [PubMed] [Google Scholar]

71. Mehta BH, Amladi ST. Evaluation of topical 0.1% tazarotene cream in the treatment of palmoplantar psoriasis: An observer-blinded randomized controlled study. Indian J Dermatol. 2011;56:40–3. [PMC free article] [PubMed] [Google Scholar]

72. Kaur I, Dogra S, Jain R, Kumar B. Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis. Indian J Dermatol Venereol Leprol. 2008;74:471–4. [PubMed] [Google Scholar]

73. Kumar U, Kaur I, Dogra S, De D, Kumar B. Topical tazarotene vs. coal tar in stable plaque psoriasis. Clin Exp Dermatol. 2010;35:482–6. [PubMed] [Google Scholar]

74. Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol. 2001;40:210–2. [PubMed] [Google Scholar]

75. Handa S. Newer trends in the management of psoriasis at difficult to treat locations: Scalp, palmoplantar disease and nails. Indian J Dermatol Venereol Leprol. 2010;76:634–44. [PubMed] [Google Scholar]

76. Veraldi S, Caputo R, Pacifico A, Peris K, Soda R, Chimenti S. Short contact therapy with tazarotene in psoriasis vulgaris. Dermatology. 2006;212:235–7. [PubMed] [Google Scholar]

77. Wollina U. Genital ulcers in a psoriasis patient using topical tazarotene. Br J Dermatol. 1998;138:713–4. [PubMed] [Google Scholar]

78. Breneman D, Sheth P, Berger V, Naini V, Stevens V. Phase II clinical trial of bexarotene gel 1% in psoriasis. J Drugs Dermatol. 2007;6:501–6. [PubMed] [Google Scholar]

79. Magliocco MA, Pandya K, Dombrovsky V, Christiansen L, Wong Y, Gottlicb AB. A randomized double blinded, vehicle- controlled, bilateral comparison trail of baxarotene gel 1% versus vehicle gel in combination with NBUVB phototreatment for moderate to severe psoriasis vulgaris. J Am Assoc Dermatol. 2006;54:115–8. [PubMed] [Google Scholar]

80. Vickers CF. Existence of reservoir in the stratum corneum. Experimental proof. Arch Dermatol. 1963;88:20–3. [PubMed] [Google Scholar]

81. Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol. 1967;48:181–3. [PubMed] [Google Scholar]

82. Bernhard J, Whitmore C, Guzzo C, Kantor I, Kalb RE, Ellis C, et al. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: Report on two double-blind, vehicle-controlled studies. J Am Acad Dermatol. 1991;25(6 Pt 2):1170–4. [PubMed] [Google Scholar]

83. Blum G, Yawalkar S. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol. 1991;25(6 Pt 2):1153–6. [PubMed] [Google Scholar]

84. Olsen EA. Efficacy and safety of fluticasone propionate 0.005% ointment in the treatment of psoriasis. Cutis. 1996;57(2 Suppl):57–61. [PubMed] [Google Scholar]

85. Katz HI, Prawer SE, Medansky RS, Krueger GG, Mooney JJ, Jones ML, et al. Intermittent corticosteroid maintenance treatment of psoriasis: A double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica. 1991;183:269–74. [PubMed] [Google Scholar]

86. Svartholm H, Larsson L, Frederiksen B. Intermittent topical treatment of psoriasis with clobetasol propionate. Curr Med Res Opin. 1982;8:154–7. [PubMed] [Google Scholar]

87. Olsen EA, Cram DL, Ellis CN, Hickman JG, Jacobson C, Jenkins EE, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol. 1991;24:443–7. [PubMed] [Google Scholar]

88. Franz TJ, Parsell DA, Halualani RM, Hannigan JF, Kalbach JP, Harkonen WS. Betamethasone valerate foam 0.12%: A novel vehicle with enhanced delivery and efficacy. Int J Dermatol. 1999;38:628–32. [PubMed] [Google Scholar]

89. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15. [PubMed] [Google Scholar]

90. Chi CC, Wang SH, Kirtschig G, Wojnarowska F. Systematic review of the safety of topical corticosteroids in pregnancy. J Am Acad Dermatol. 2010;62:694–705. [PubMed] [Google Scholar]

91. Friedlander SF, Hebert AA, Allen DB. Fluticasone Pediatrics Safety Study Group. Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. J Am Acad Dermatol. 2002;46:387–93. [PubMed] [Google Scholar]

92. Feldman SR, Yentzer BA. Topical clobetasol propionate in the treatment of psoriasis: A review of newer formulations. Am J Clin Dermatol. 2009;10:397–406. [PubMed] [Google Scholar]

93. Poulin Y, Papp K, Bissonnette R, Guenther L, Tan J, Lynde C, et al. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. J Dermatolog Treat. 2010;21:185–92. [PubMed] [Google Scholar]

94. Binderup L, Bramm E. Effects of a novel Vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol. 1988;37:889–95. [PubMed] [Google Scholar]

95. Highton A, Quell J. Calcipotriene ointment 0.005% for psoriasis: A safety and efficacy study. Calcipotriene study group. J Am Acad Dermatol. 1995;32:67–72. [PubMed] [Google Scholar]

96. Ramsay CA. Management of psoriasis with calcipotriol used as monotherapy. J Am Acad Dermatol. 1997;37(3 Pt 2):S53–4. [PubMed] [Google Scholar]

97. Mason AR, Mason J, Cork M, Dooley G, Edwards G. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2009;2:CD005028. [PubMed] [Google Scholar]

98. Green C, Ganpule M, Harris D, Kavanagh G, Kennedy C, Mallett R, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol. 1994;130:483–7. [PubMed] [Google Scholar]

99. Lebwohl M, Siskin SB, Epinette W, Breneman D, Funicella T, Kalb R, et al. A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis. J Am Acad Dermatol. 1996;35(2 Pt 1):268–9. [PubMed] [Google Scholar]

100. Taraska V, Tuppal R, Olesen M, Bang Pedersen C, Papp K. A novel aerosol foam formulation of calcipotriol and betamethasone has no impact on HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris. J Cutan Med Surg. 2016;20:44–51. [PMC free article] [PubMed] [Google Scholar]

101. Gerritsen MJ, Van De Kerkhof PC, Langner A. Long-term safety of topical calcitriol 3 microg/g ointment. Br J Dermatol. 2001;144(Suppl 58):17–9. [PubMed] [Google Scholar]

102. van de Kerkhof PC, Berth-Jones J, Griffiths CE, Harrison PV, Hönigsmann H, Marks R, et al. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol. 2002;146:414–22. [PubMed] [Google Scholar]

103. Veien NK, Bjerke JR, Rossmann-Ringdahl I, Jakobsen HB. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol. 1997;137:581–6. [PubMed] [Google Scholar]

104. Trémezaygues L, Reichrath J. Vitamin D analogs in the treatment of psoriasis: Where are we standing and where will we be going? Dermatoendocrinol. 2011;3:180–6. [PMC free article] [PubMed] [Google Scholar]

105. Laws PM, Young HS. Topical treatment of psoriasis. Expert Opin Pharmacother. 2010;11:1999–2009. [PubMed] [Google Scholar]

106. Pèrez A, Chen TC, Turner A, Raab R, Bhawan J, Poche P, et al. Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin d3) for the treatment of psoriasis. Br J Dermatol. 1996;134:238–46. [PubMed] [Google Scholar]

107. Kragbelle K. Vitamin D3 analogues. Dermatol Clin. 1996;13:835–8. [Google Scholar]

108. Patel B, Siskin S, Krazmien R, Lebwohl M. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol. 1998;38(6 Pt 1):1010–1. [PubMed] [Google Scholar]

109. Darley CR, Cunliffe WJ, Green CM, Hutchinson PE, Klaber MR, Downes N. Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris. Br J Dermatol. 1996;135:390–3. [PubMed] [Google Scholar]

110. Takahashi H, Ibe M, Kinouchi M, Ishida-Yamamoto A, Hashimoto Y, Iizuka H. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci. 2003;31:21–8. [PubMed] [Google Scholar]

111. Durakovic C, Ray S, Holick MF. Topical paricalcitol (19-nor-1 alpha, 25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: A pilot study. Br J Dermatol. 2004;151:190–5. [PubMed] [Google Scholar]

112. Helfrich YR, Kang S, Hamilton TA, Voorhees JJ. Topical becocalcidiol for the treatment of psoriasis vulgaris: A randomized, placebo-controlled, double-blind, multicentre study. Br J Dermatol. 2007;157:369–74. [PubMed] [Google Scholar]


Page 2